Biodol Therapeutics
Pierre SOKOLOFF
Chief Scientific Officer
Who are we?
BIODOL Therapeutics develops first-in-class compounds for chronic pain, including the first-ever specific treatment of neuropathic pain (NP). Moreover, BIODOL Therapeutics’ treatment may help fighting the “Opioid Crisis”. BIODOL Therapeutics made a breakthrough discovery on the origin and maintenance of NP. These results are published in Nature Communications 2018. BIODOL Therapeutics showed that inhibiting FLT3 reduces allodynia and pain hypersensitivity, the two main symptoms of NP, without affecting normal nervous system functioning. Moreover, recent discoveries by BIODOL Therapeutics (unpublished but patented results) extend the scope of indications to those amenable to treatment with opioids, which could be improved (morphine-dose sparing).